相关实验视频
Updated: Jul 25, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
帕金森病 - 目前的治疗方法
Ryan Wang1, Ludy C Shih1,2
1Department of Neurology, Boston Medical Center.
Current opinion in neurology
|June 27, 2023
概括
最近的帕金森病 (PD) 研究为运动症状 (如波动和动力障碍) 提供了改进的治疗方法. 新的疗法也显示出对非运动症状的承诺,提高患者的生活质量.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 老年病的医生 老年病的医生
背景情况:
- 帕金森病 (PD) 呈现复杂的运动和非运动症状,影响患者的生活质量.
- 最佳的症状管理是至关重要的,因为目前的治疗方法无法阻止疾病的进展.
结论:
- 虽然缺乏改变疾病的治疗方法,但在帕金森病的症状管理方面取得了重大进展.
- 临床医生必须了解不断发展的治疗选择,以应对PD的多方面的挑战.
相关概念视频
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Drug Therapy
74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
74
Psychosis: Goals of Pharmacotherapy
171
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
171
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
197
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
197

